LifeStance Health posts strong Q3 2026 results and lifts full‑year outlook
LifeStance Health Group reported third‑quarter 2026 revenue of $455.9 million, up 25% year‑over‑year, and net income of $22.4 million. The company raised its full‑year 2026 revenue guidance to $1.741‑$1.761 billion and adjusted EBITDA guidance to $242‑$250 million. Management highlighted growth in visit volumes, clinician headcount and specialty‑care services, while noting a planned EHR rollout that may modestly curb 2027 growth.
Why it matters
The higher revenue and earnings beat led analysts such as BMO Capital to lift their price target to $16.00. The raised guidance suggests stronger earnings potential for the rest of 2026, which could support the stock’s recent gains.
Key facts
- 1Q3 2026 revenue was $455.9 million, a 25% increase from the prior year. stocktitan.net
- 2Net income for the quarter was $22.4 million. stocktitan.net
- 3Full‑year 2026 revenue guidance was lifted to $1.741 billion‑$1.761 billion. stocktitan.net
- 4Full‑year 2026 adjusted EBITDA guidance was raised to $242 million‑$250 million. stocktitan.net
- 5Visit volumes rose 17% to 2.7 million in the quarter. stocktitan.net
- 6Clinician base grew 11% to 8,863 clinicians, adding 321 clinicians in Q3. stocktitan.net
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.